Objective: Doxorubicin is an efficient anthracycline drug for the treatment of tumor, however, its cardiotoxicity restricts the clinical application. Shenfu decoction has good clinical effect, but the pharmacological mechanism is not fully clarified. Method: The active components and potential targets of shenfu decoction were screened by TCMSP database, disease targets of doxorubicin-induced cardiotoxicity were collected by Genecards and OMIM database, and the network diagram of “drug-components-target-disease” was constructed by Cytoscape software. PPI network was constructed by STRING database. The target of action of the drug and the disease gene were mapped for GO and KEGG signal pathway analysis. Results: The study found that there are 52 main effective components of shenfu decoction, and 76 genes are involved in the potential therapeutic targets, among which 24 genes are potential targets of shenfu decoction in the treatment of doxorubicin-induced cardiotoxicity. The protein interaction network suggested that BCL2、BAX、CASP9、CASP3、MAPK8 may be the core target. GO enrichment analysis showed 52 cellular biological processes, and enrichment analysis of KEGG pathway revealed 99 involved signaling pathways, including TNF, apoptosis signaling pathways , etc. Conclusion: In this study, the network of “ drug-components-target-disease ” was constructed through network pharmacology, and it was found that the mechanism of “ shenfu decoction” in the treatment of doxorubicin-induced cardiotoxicity involves multiple targets and pathways, which is conducive to guiding clinical medication.